Neuphoria Therapeutics Inc (NASDAQ:NEUP) — Market Cap & Net Worth
Market Cap & Net Worth: Neuphoria Therapeutics Inc (NEUP)
Neuphoria Therapeutics Inc (NASDAQ:NEUP) has a market capitalization of $23.29 Million ($23.29 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24553 globally and #5032 in its home market, demonstrating a 6.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuphoria Therapeutics Inc's stock price $5.22 by its total outstanding shares 5390895 (5.39 Million). Analyse NEUP cash flow conversion to see how efficiently the company converts income to cash.
Neuphoria Therapeutics Inc Market Cap History: 2024 to 2026
Neuphoria Therapeutics Inc's market capitalization history from 2024 to 2026. Data shows growth from $18.49 Million to $28.14 Million (0.00% CAGR).
Index Memberships
Neuphoria Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #712 of 976 |
Weight: Neuphoria Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuphoria Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuphoria Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.87x
Neuphoria Therapeutics Inc's market cap is 0.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $20.92 Million | $23.95 Million | -$565.77K | 0.87x | N/A |
Competitor Companies of NEUP by Market Capitalization
Companies near Neuphoria Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Neuphoria Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Neuphoria Therapeutics Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Neuphoria Therapeutics Inc's market cap moved from $18.49 Million to $ 28.14 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $28.14 Million | +34.54% |
| 2025 | $20.92 Million | +13.12% |
| 2024 | $18.49 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Neuphoria Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.29 Million USD |
| MoneyControl | $23.29 Million USD |
| MarketWatch | $23.29 Million USD |
| marketcap.company | $23.29 Million USD |
| Reuters | $23.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more